Cancer Vaccine mRNA-4157 Improves RFS, DMFS in High-Risk Melanoma
Adding the mRNA-4157 vaccine to pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk, resected melanoma in a phase 2 trial.
Adding the mRNA-4157 vaccine to pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk, resected melanoma in a phase 2 trial.
Sacituzumab govitecan improves outcomes vs physician’s choice of treatment in patients with endocrine-resistant, HR+, HER2- metastatic breast cancer, results from the phase 3 TROPiCS-02 study suggest.
Perioperative toripalimab plus chemotherapy improves event-free survival over chemotherapy alone in stage III non-small cell lung cancer, a phase 3 study suggests.
The ADAURA trial is the first global phase 3 study to show an overall survival benefit with targeted treatment in resected, EGFR-mutated, stage IB-IIIA non-small-cell lung cancer, according to study presenter Roy S. Herbst, MD, PhD.
If approved, vorasidenib could become a new standard of care for low-grade IDH1/2-mutated gliomas, according to an ASCO discussant.
Curative surgery for non-small cell lung cancer after treatment with nivolumab plus relatlimab is as safe as surgery after nivolumab alone, the NEOpredict-Lung study suggests.
Some patients with early HER2-positive breast cancer can safely forgo neoadjuvant chemotherapy, results of the PHERGain trial suggest.
UCPVax, an anti-telomerase vaccine, has demonstrated immunogenicity in a phase 2 trial of patients with MGMT unmethylated glioblastoma.
Luspatercept appears more effective than epoetin alfa for treating anemia in patients with ESA-naïve, transfusion-dependent, lower-risk MDS.
Elderly women with breast cancer who report pain or have impaired functional status should be screened for malnutrition, a study suggests.